Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Altus Formulation Lnc currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit, indicating a highly focused prosecution effort. KASSA, TIGABU is the busiest examiner for this portfolio, overseeing 1 pending office action. The outcome of the company's current patent filing is therefore entirely dependent on the examination practices and decisions of this specific individual.
The involvement of 1 distinct art unit suggests that the technology is categorized within a specialized administrative group of Biotechnology & Pharmaceuticals. For the practitioner, this means that prosecution strategy must be tailored to the specific norms and prior art search patterns of that unit. Since KASSA, TIGABU is the only examiner currently handling a pending matter for Altus Formulation Lnc, their historical data regarding allowance rates and interview receptivity will be the most important factor in the prosecution process.
With 1 pending office action, there is no opportunity to compare different examiner responses or art unit efficiencies within the current portfolio. The practitioner should focus on building a clear record with the assigned examiner to resolve the 1 pending office action. Because the portfolio is concentrated in a single art unit, understanding the specific preferences of that group is essential for advancing the patent objectives of Altus Formulation Lnc.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042145 | DUAL ANALGESIC/ANTI-INFLAMMATORY COMPOSITIONS COMPRISING CB2 RECEPTOR AGONISTS, COMBINATIONS, AND METHODS OF USE THEREOF | KASSA, TIGABU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042145 | DUAL ANALGESIC/ANTI-INFLAMMATORY COMPOSITIONS COMPRISING CB2 RECEPTOR AGONISTS, COMBINATIONS, AND METHODS OF USE THEREOF | KASSA, TIGABU | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18042145 | DUAL ANALGESIC/ANTI-INFLAMMATORY COMPOSITIONS COMPRISING CB2 RECEPTOR AGONISTS, COMBINATIONS, AND METHODS OF USE THEREOF | KASSA, TIGABU | 1619 | §102§103§112 | Non-Final OA | — | Pending | Feb 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAltus Formulation Lnc has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Tigabu Kassa has the most, with 1 of Altus Formulation Lnc's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
